Opening of enrollment in US of Phase I CRC study announced today at

coloCan

www.prnewswire.com

title: Oncolytics Biotech Inc Announces Opening of Enrollment in US Phase I Colorectal Cancer Study

This involves using REOLYSIN (this firm's drug) in combo with FOLFIRI for those with oxaliplatin refractory/intolerant Kras mutant CRC



Meanwhile,a company called Pro-Pharma seems to be getting positive feedback from FDA for Phase III trial design for DAVANAT, which is its CRC drug in progress.......see:businesswire.com

dont know if this will help anyone......steve

Lovekitties

Thanks Steve
You are a gem to keep up with all the latest and greatest and keeping everyone here in the loop.

Thanks for being you.

Marie who loves kitties